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1. Introduction
Endometrial cancer is the most frequent gynecologic malignancy in the United States and the
sixth most frequent malignancy worldwide. The highest incidence of endometrial cancer is
reported in North America, followed by Central and Eastern Europe. Conversely, the lowest
incidence of endometrial cancer is reported in developing countries such as Central and
Western Africa [1]. In the United States, roughly 47,000 new cases of endometrial cancer and
8,000 related deaths are recorded yearly [2]. The incidence of endometrial cancer has dramat‐
ically increased by 21% since 2008, and unfortunately, the mortality rate per 100,000 cases has
increased by more than 100% over the last two decades, and by 8% since 2008 [3].
At the time of clinical diagnosis, it has been estimated that approximately 75% of endometrial
cancer patients have early stage disease (FIGO stage I and II) with a 5-year overall survival of
80% to 90% [4, 5]. However, nearly 10% to 15% of patients with early-stage disease develop
recurrences after the primary surgical treatment [6, 7]. Conversely, a very small group of
patients are unlucky and present with advanced stage disease with unfortunate prognoses.
The 5-year survival rates for regional disease (FIGO stage III) and distant disease (FIGO stage
IV) are 57% and 19%, respectively [8].
Management of endometrial cancer can be very challenging, even for early-stage disease. The
objective of the chapter is to comprehensively shed light on the past, present and future
perspectives on the different treatment modalities employed in the management of endome‐
trial cancer.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. The role of surgery in management of endometrial cancer:
Despite the vast majority of patients diagnosed with endometrial cancer present to clinical
attention with early stage disease limited to uterus, metastatic disease is recognized in a
substantial proportion when comprehensive surgical staging is carried out [9]. In 1988, the
International Federation of Gynecologists and Obstetricians (FIGO) officially suggested
surgical staging as part of the primary management plan for endometrial cancer. Despite the
recent amendments of the staging system in 2009, comprehensive staging (total hysterectomy,
bilateral salpingooophorectomy, peritoneal cytology, intraoperative bilateral pelvic and para-
aortic lymph node dissection) continue to be recommended [10-12].
The major advantages of comprehensive surgical staging are directly related to the diagnosis,
prognosis, and proper categorization of patients who may benefit from adjuvant therapy.
FIGO endometrial cancer staging is chiefly based on surgical pathology and comprehensive
surgery permits accurate delineation of disease extent.
2.1. The role of laparotomy, conventional laparoscopy and robotic-assisted laparoscopy in
management of endometrial cancer
Conventionally, laparotomy has been the primary mode for surgical staging in patients with
endometrial cancer [10-12].
However, several studies examined the practicality of minimally invasive approaches such as
laparoscopy for surgical staging of endometrial cancer [13,14].
Afterwards, randomized controlled trials endeavored to compare laparotomy versus conven‐
tional laparoscopic approaches. In Gynecologic Oncology Group Study (GOG) LAP2, more
than 2000 patients with endometrial cancer were randomized to receive comprehensive
surgical staging via conventional laparoscopy or laparotomy [15]. Conventional laparoscopic
arm experienced fewer post-surgery complications (14% vs 21%, respectively; p=0.0001),
shorter hospitalization rates over 2 days (52% vs 94%, respectively; p=0.0001), however, longer
operating periods (204 minutes vs 130 minutes, respectively; p=0.001). The incidence of
intraoperative adverse events was similar. Operative conversion from conventional laparo‐
scopy to laparotomy happened in roughly 17.5% of patients with body mass index (BMI) of
25, and 26.5% of patients with BMI of 35 and above, mainly due to poor surgical exploration.
Over the 6-week recovery period, the conventional laparoscopic arm patients articulated much
higher scores on multiple quality-of-life aspects (less pain, more cosmetics, faster resumption
of daily and social activities) [16].
A recently published meta-analysis of survival data compiling 3 randomized controlled
clinical trials did identify survival differences between the surgical approaches in patients
receiving the conventional laparoscopy and laparotomy for surgical staging of endometrial
cancer [17]. A secondary survival analysis showed largely comparable 5-year overall survival
rate (around 90% in both groups) and 3-year recurrence rate (around 11% vs 10% in conven‐
tional laparoscopy and laparotomy groups, respectively). Based on these findings, it was
concluded that conventional laparoscopic approach was not inferior to laparotomy for surgical
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staging of endometrial cancer [15,18]. Rather, it was concluded that conventional laparoscopic
surgical management of endometrial cancer is superior to laparotomy in terms of hospital stay
and short-term safety with comparable overall survival and free-recurrence rates. Hence,
conventional laparoscopy ―whenever technically possible― should be considered as the
recommended (primary) approach for comprehensive surgical staging in management of
patients with endometrial cancer.
The daVinci Surgical System (Intuitive Surgical, Sunnyvale, CA) is widely used by many
gynecologic oncologists and designed to facilitate robotic-assisted laparoscopy. Despite the
many  benefits  (seated  and  long-distance  operating  setting,  three-dimensional  image  of
surgical  field,  tremor  omission,  etc),  one  of  the  major  disadvantages  is  lack  of  haptic
feedback [2].
There are multiple published retrospective case series studies that journeyed to explore the
use of robotic-assisted laparoscopy for comprehensive surgical staging of endometrial cancer
[19,20]. Primary results showed that robotic-assisted laparoscopy was feasible and safe (highly
governed by hands-on surgical expertise). Unfortunately, robotic-assisted laparoscopy has not
been prospectively compared in randomized controlled trials to conventional laparoscopy for
evaluating the efficacy of endometrial cancer surgical staging, and hence data about survival,
safety, and performance differences are lacking. Nevertheless, current literature data point out
that robotic-assisted laparoscopy has advantages closely comparable to conventional laparo‐
scopy. Moreover, over time, technical expertise can be simply acquired with robotic assistance
as compared to conventional laparoscopy, and thus enabling the achievement of complete
comprehensive staging of endometrial cancer in the obese and morbidly obese patients, as
laparotomy possesses high potential adverse events in such populations [21]. For communities
concerned about financial matters, cost differences between surgical approaches for staging
endometrial cancer has been reported [22]. Laparotomy was the most expensive, followed by
robotic-assisted laparoscopy, and followed by conventional laparoscopy.
Port-site tumor implantation taking place in patients undergoing minimally invasive laparo‐
scopic techniques for gynecologic cancers is always a major concern for many patients and
surgeons [10]. Generally speaking, the incidence of port-site tumor metastatic deposits
following laparoscopic procedures in patients with malignant cancer is very minimal, and
mostly takes place in the setting of already locally widely spread intra-abdominal disease or
distant metastatic disease [23]. Precisely, the risks of port-site tumor implantation in patients
with early-stage endometrial cancer following laparoscopic procedures (conventional or
robotic-assisted approaches) are very low (less than 1%) [24]. Therefore, minimally invasive
laparoscopic techniques can be used safely, to a greater degree, in patient with early-stage
disease.
2.2. The role of lymphadenectomy in management of endometrial cancer
The issue of bilateral pelvic and para-aortic lymphadenectomy for surgical staging of endo‐
metrial cancer remains a topic of argument [10, 25-27]. Although lymphadenectomy is required
for accurate staging, lymphadenectomy should generally be considered in patients with high
risk for lymph nodal involvement [28-31]. Such risk factors include: tumor grade 3 (poorly
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differentiated), more than 50% of myometrial invasion, lymphovascular space invasion, non-
endometrioid histology (serous, clear cell, undifferentiated, small cell, anaplastic, etc), cervical
stromal involvement, advanced FIGO stage (III and IV), and older age (above 60 years) [28].
Several randomized controlled clinical trials demonstrated no survival benefits from system‐
atic lymphadenectomy in patients with early-stage and low-risk endometrial cancer. Benedetti
Panici and colleagues [25] explored the effect of systematic lymphadenectomy in patients with
stage I endometrial cancer and documented no difference in overall survival (90% vs. 86%)
and disease-free survival (80% vs. 82%) rates between lymphadenectomy and no lymphade‐
nectomy arms. Moreover, the ASTEC trial from United Kingdom [26] studied approximately
1400 patients with endometrial cancer limited to uterus, and showed no recurrence-free or
overall survival benefits from pelvic lymphadenectomy in patients with early-stage endome‐
trial cancer. Another randomized clinical trial from Italy [25] reported no difference in rates
of survival or recurrence between patients who underwent lymphadenectomy versus who did
not undergo lymphadenectomy for early-stage endometrial cancer. Furthermore, 2 cohort
studies showed that patients with low-risk endometrial cancer disease (neoplasm size ≤2 cm,
less than 50% myometrial invasion, grade 1 and 2 endometrioid neoplasms) had no lympha‐
denopathy at time of surgical staging and did not gain advantage from systematic lympha‐
denectomy [30, 31]. Collectively, these data suggest no therapeutic benefit of
lymphadenectomy in patients with early-stage and low-risk endometrial cancer.
Bristow and associates [32] conducted a retrospective cohort study examining 41 patients with
advanced stage IIIC endometrial cancer, and found statistically significant disease-specific
survival benefit of 37.5 months versus 8.8 months (p=0.006) between patients who received
optimal (completely debulked) lymphadenectomy and patients who received suboptimal
lymphadenectomy groups. They concluded that patients with stage IIIC endometrial carcino‐
ma, complete debulking of gross nodal disease and subsequent administration of combined
adjuvant radiation therapy and chemotherapy are correlated with improved disease-specific
survival.
There are continuing disputes regarding whether to perform complete bilateral para-aortic
lymphadenectomy in all patients. Positive para-aortic lymph nodes can occur in the absence
of pelvic lymphadenopathy [30, 33]. Abu-Rustum and colleagues [33] identified 1.6% rate of
para-aortic lymphadenopathy in 734 patients with negative pelvic lymphadenopathy and low-
and high-grade endometrial cancer. As such, the current practice is to perform pelvic lym‐
phadenectomy, in addition to para-aortic lymphadenectomy, or to propose sentinel lymph
node mapping [34, 35]. Khoury-Collado and partners [34] evaluated a sum of 266 patients with
endometrial cancer for lymph node mapping. Sentinel lymph node recognition was positive
in 223 patients (84%). The utility of sentinel lymph node mapping may surface as a plausible
suggestion to decide whether patients with early stage endometrial cancer will get advantage
from pelvic and/or para-aortic lymph node evaluation.
Other studies recommend that para-aortic lymphadenectomy should be offered to patients
with advanced stage and high-risk histopathological endometrial cancer [29-32]. Mariani and
colleagues [30] explored 281 patients who had lymphadenectomy at the time of endometrial
cancer staging and identified that approximately 22% of high-risk patients had lymph node
Contemporary Gynecologic Practice160
invasion. Of these, roughly 33% had isolated pelvic lymphadenopathy, 16% had isolated para-
aortic lymphadenopathy and 51% had both pelvic and para-aortic lymphadenopathy.
Although straightforward disease-free survival and overall survival benefits of pelvic and
para-aortic lymphadenectomy have not been solidly reported, the procedure of lymphade‐
nectomy offers accurate staging of endometrial cancer, and recognizes node-positive patients
who may benefit from adjuvant treatment.
2.3. The role of “Cytoreduction” in management of recurrent endometrial cancer
Around 25% of endometrial cancer related mortality is primarily due to recurrent disease [6,
36, 37]. More than half of patients with endometrial cancer experience recurrence following
the initial surgical treatment [38]. Recurrence rates can be as low as 15% in early-stage disease
and benign pathology, and as high as 50% in late-stage disease and aggressive pathology
[39-41]. Prognosis of patients with recurrent disease and peritoneal metastasis is very graving
(median survival less than 12 months) [42, 43]. Optimal Surgical debulking (whenever
feasible), even with multiple recurrences, is the standard of care followed with adjuvant
radiotherapy, chemotherapy or hormonal therapy [43].
Bristow and associates [44] reported a cohort of 61 patients undergoing cytoreduction for
recurrent endometrial cancer. Optimal cytoreduction (no gross residual disease) was achieved
in 66% of patients and yielded longer median recurrence-free survival rates of 39 months as
opposed to patients with suboptimal cytoreduction of only 13 months (p=0.0005).
Awtrey and partners [45] reported a cohort of 27 patients undergoing cytoreduction for
recurrent endometrial cancer. Optimal cytoreduction (no gross residual disease) and subop‐
timal cytoreduction (less than 2 cm residual disease) was achieved in roughly 56% and 67% of
patients, respectively, and, yielded longer median survival rates (43 months vs. 10 months,
respectively; p< 0.05).
In the above-mentioned two studies, the absence of residual disease was correlated with
improved disease-free survival and overall survival rates [44, 45]. Collectively, Barlin and
colleagues [46] conducted a meta-analysis and showed that optimal cytoreduction to no
macroscopic disease was correlated with overall survival benefits ranging from 9 to 25 months
in patients with recurrent endometrial cancer.
2.4. The role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in management of
recurrent endometrial cancer
The utilization of hyperthermic intraperitoneal chemotherapy (HIPEC) has yielded signifi‐
cantly substantial improvements in disease-free survival and overall survival rates in patients
with peritoneal recurrence from pseudomyxoma peritonei [47], colon cancers [48], gastric
cancers [49] and ovarian cancers [50]. Its use in management of recurrent endometrial cancer
is minimal and has not gained much popularity.
Bakrin and colleagues [43] studied the combination of cytoreduction and HIPEC in 5 patients
with recurrent endometrial cancer. Optimal cytoreduction was achieved in all patients. HIPEC
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was carried out with mitomycin C and cisplatin. Intraoperative and postoperative adverse
events were uneventful. Two patients developed early recurrences at 2 and 10 months and
both died afterwards. The remaining three patients were alive and disease-free at 7, 23 and 39
months with fair performance status.
Abu-Zaid and colleagues [51] studied the combination of cytoreduction and HIPEC in 2 and
4 patients with primary advanced and recurrent endometrial cancer, respectively. Optimal
cytoreduction was achieved in 5 patients. HIPEC was carried out with doxorubicin and
cisplatin. Intraoperative and postoperative adverse events were uneventful. All patients
received adjuvant chemotherapy (carboplatin and paclitaxel). Despite optimal debulking, one
patient with an aggressive histology (clear cell carcinoma) relapsed within 6 months and died
5 months later because of metastatic spread to liver and pelvis. One patient with suboptimal
cytoreduction (more than 2 cm residual disease) developed liver recurrence within 3 months
and was still alive with disease at a follow-up of 6 months. The remaining patients were alive
and disease-free without recurrence at follow-up at 35, 34, 19, and 7 months.
Another study done in France [52] included 13 patients treated with cytoreduction and HIPEC
for management of endometrial cancer with peritoneal metastases. One patient was lost to
follow-up. Following HIPEC, three patients died before the first year, and two patients
approximately died at first year and first year and half, respectively. Three patients were alive
with disease, and 4 patients were alive without disease, between approximately 2 and 125
months period.
In the above-mentioned studies, disease-free survival and overall survival rates were largely
affected by degree of peritoneal cancer index, cytoreduction completeness and tumor pathol‐
ogy [43, 51, 52].
Despite promising results, almost all the existing studies are limited by their retrospective
study designs, lack of randomized controlled trials, short follow-up periods and small sample
sizes. This is an interesting arena for research and further studies are needed.
The logic for using HIPEC is chiefly attributed to the straightforward temperature-improved
cytotoxicity of the intraperitoneal chemotherapeutic agents [53, 54]. Moreover, HIPEC aims to
deeply penetrate the residual microscopic deposits [53, 54]― the primary source of surgical
failure and early recurrence rates [43, 51, 52, 55, 56] in recurrent endometrial cancer. Moreover,
HIPEC avoids the needless chemotherapy-related systemic toxicities while maximizing the
local concentrations [57]. The most frequently used HIPEC agents include cisplatin [58]
doxorubicin [59] and mitomycin C [60].
Generally, morbidity and mortality of cytoreduction and HIPEC are greatly influenced by the
surgeons’ expertise and learning curve [61]. A recent systematic review by Chua and collea‐
gues [62] demonstrated that the morbidity rate associated with cytoreduction and HIPEC
range from approximately 12% to 52%, whereas mortality rate range from 1% to 6%.
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3. The role of adjuvant radiation therapy in management of endometrial
cancer
The role of radiation therapy in management of endometrial cancer is still under investigation
with inconsistent findings and there are no solid conclusions. Improvement in disease-free
survival rates is noted only.
3.1. Pelvic external beam radiation therapy (EBRT)
The efficacy of adjuvant external beam radiotherapy (EBRT) was studied in five randomized
clinical trials [40, 41, 63-69]. Only ASTEC/EN.5 clinical trial included a substantial percentage
of patients with aggressive serous or clear cell histology (6.5%) [64]. Conversely, in all the other
remaining trials, endometrioid adenocarcinoma was the most predominant histology. All
trials demonstrated advantages of EBRT in terms of loco-regional control (disease-free
survival) only, but failed to yield any survival benefits. Furthermore, at a median follow-up
of 21 years, an update of Oslo trial demonstrated that patients under 60 years of age who were
administered adjuvant EBRT experienced lower overall survival rates and higher risks of
harboring secondary malignancies, as high as 30% [69]. Moreover, in the PORTEC trial,
patients who received EBRT had worse quality of life as opposed to the observation patients
[68]. The EBRT toxicities commonly involved the urogenital and gastro-intestinal tract systems
and included urinary leakage and urgency, in addition to frequent diarrheal attacks and stool
incontinence. These findings were endorsed in two recently published meta-analyses [70, 71].
Subgroups analyses were completed and demonstrated that EBRT had improved disease-free
survival in patients with high risk of recurrence (p=0.03), however, EBRT had harmful
outcomes on overall survival in patients with low or intermediate risk of recurrence (p=0.03)
[70]. Therefore, it can be concluded that adjuvant EBRT should be largely employed for
management of high-risk patients with primary advanced or recurrent endometrial cancer.
Moreover, long-term related toxicities of EBRT should be considered wisely when adjuvant
EBRT is selected for younger patients. EBRT should be selected in patients with high-risk
histological features, positive lymph nodes or primary advanced stage disease (III/IV) [28].
The suggested histopathological features for determining high-risk disease include: tumor
grade 3 (poorly differentiated), more than 50% of myometrial invasion, lymphovascular space
invasion, non-endometrioid histology (serous, clear cell, undifferentiated, small cell, anaplas‐
tic, etc), cervical stromal involvement, advanced stage disease (FIGO stage III and IV) and older
age (more than 60 years) [28].
3.2. Vaginal brachytherapy
The efficacy of adjuvant vaginal brachytherapy (VB) was evaluated in two randomized clinical
trials [72, 73]. Patients with serous or clear cell histology were exempted from the studies and
only patients with endometrioid adenocarcinomas were included. In low-risk patients with
endometrial cancer (stage IA−B, grades 1–2), vaginal brachytherapy did not add benefit over
observation [72]. However, in PORTEC-2 clinical trial, in high-intermediate risk patients,
vaginal brachytherapy was demonstrated to be non-inferior to EBRT and provided comparable
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loco-regional control (less than 2% at 5-year period for both arms), disease-free survival and
overall survival [63, 73]. Vaginal brachytherapy is associated with considerably fewer gastro-
intestinal tract toxicities (less diarrheal attacks and stool incontinence) and a better functioning
social quality of life [72-74]. Sorbe and colleagues [63] compared combination of EBRT and
brachytherapy versus brachytherapy alone: there was no 5-year overall survival benefit (89%
and 90%, respectively; p=0.548). However, the 5-year pelvic and loco-regional recurrences
were much more common in the vaginal brachytherapy alone group (1.5% and 5%, respec‐
tively; p=0.013). It was concluded that combined radiation therapy (EBRT and vaginal
brachytherapy) should possibly be reserved for high-risk patients, whereas vaginal brachy‐
therapy alone should be reserved for purely medium-risk patients.
In conclusion, vaginal brachytherapy, to a certain degree, effectively decreases the risk of
vaginal recurrence in patients with risk factors while minimizing the radiation-related
toxicities. In patients with early-stage endometrial cancer, vaginal brachytherapy should the
adjuvant treatment of choice over EBRT.
4. The role of adjuvant chemotherapy in management of endometrial
cancer
The role of adjuvant chemotherapy has been studied in patients with early-stage intermediate-
to-high risk endometrial cancer, as well as patients with primary advanced, inoperable or
recurrent late-stage endometrial cancer [39, 75-81]. The efficacy of postoperative chemotherapy
was studied in a total of nine randomized clinical trials [39, 75-81]. The following trials included
a substantial percentage of patients with the aggressive serous or clear cell histology: NSGO-
EORTC (37%), GOG122 (25%), GOG184 (18%) [39, 78, 81]; the vast majority of patients had
endometrioid adenocarcinoma histology.
Three clinical trials compared chemotherapy schedules with radiotherapy [39, 75, 76]. Two
randomized clinical trials compared between one group of patients receiving cyclophospha‐
mide–doxorubicin–cisplatin, and one group of patients receiving pelvic EBRT. There were no
benefits between both groups with respect to 5-year progression-free survival and overall
survival rates [75, 76]. Conversely, GOG122 trial demonstrated statistically significant 5-year
progression-free survival (50% and 38%, respectively; p=0.007) and overall survival (55% and
42%, respectively; p=0.004) rates between one group of patients receiving doxorubicin–
cisplatin, and one group of patients receiving EBRT. All patients studied in COG122 study had
advanced stage disease (III/IV) with less than 2 cm residual disease post-surgery [39].
Four clinical trials explored the advantage of adding a chemotherapy regimen to EBRT [77-79].
Three clinical trials (MaNGO ILIADE-III, Kuoppala and GOG34) demonstrated no progres‐
sion-free survival or overall survival benefits of combined treatment (chemotherapy plus
radiotherapy) versus EBRT alone. However, the NSGO-EORTC trial showed that postopera‐
tive chemotherapy was correlated with an improved 5-year progression-free survival rate (79%
and 72%; p=0.004), but not overall survival benefits [77]. There are discrepancies for the
reported results among studies and these can be attributed to the variances of treatment
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methods such as: percentage of patients with advanced stage disease (stage III–IV) and choice
of chemotherapy regimens. Therefore, such studies must be interpreted with caution.
However, overall, a recently published meta-analysis covering a total of nine clinical trials
showed that adjuvant chemotherapy was correlated with a statistically significant overall
survival benefit (HR=0.74 [95% CI: 0.62–0.89]; p=0.0009), associating with an absolute differ‐
ence of 3% in 5-year survival rate [80].
Two clinical trials endeavored to compare chemotherapy regimens and the superiority of
either of them in terms of progression-free survival or overall survival rates failed to take place
[81, 82]. Fujimura and colleagues [81] considered one group of patients with cyclophospha‐
mide–doxorubicin–cisplatin, and one group of patients with etoposide–cisplatin. Homesley
and colleagues (the GOG184 trial) [82] considered one group of patients for doxorubicin–
cisplatin–placitaxel, and one group of patients for doxorubicin–cisplatin. In this study, the
addition of paclitaxel to a cisplatin–doxorubicin regimen was accompanied with substantial
chemotherapy-related side effects, mainly neurologic and hematologic [82].
There is an ongoing randomized clinical trial GOG209 phase III (paclitaxel–carboplatin versus
paclitaxel–doxorubicin–cisplatin for management of recurrent/advanced endometrial cancer)
[83]. Preliminary findings demonstrated that carboplatin–placitaxel combination was not
inferior to doxorubicin–cisplatin–placitaxel with respect to progression-free survival (compa‐
rable median of 13-14 months; p >0.05) and overall survival (32 versus 38 months, respectively;
no statistical significant difference: p >0.05) and was associated with reduced toxicity: periph‐
eral neuropathic toxicity grade 2 or higher (19% versus 26%), thrombocytopenia (12% versus
23%), metabolic imbalances (8% versus 14%), vomiting (4% versus 7%) and diarrhea (2% versus
6%) [10]. However, in consideration of the paclitaxel–doxorubicin–cisplatin associated toxicity,
the combination of paclitaxel–carboplatin probably stands as the most preferred utilized
chemotherapy regimen, and its administration is supported by the GOG209 trial above [83]
and many other retrospective studies [51]. More studies are needed.
Previous studies have demonstrated that neoadjuvant chemotherapy with subsequent optimal
cytoreduction for patients presenting with primary advanced endometrial cancer yielded no
residual disease in 79% to 100% of all patients treated [84, 85]. Additional studies are needed.
5. The role of hormonal therapy in management of endometrial cancer
Many endometrial cancers express estrogen (ER) and progesterone (PR) receptors, and hence
hormonal therapy can be applied as reasonable therapeutic choice in patients with hormone
receptor-positive endometrial cancers. The presence of ER and PR receptors largely provides
a powerfully predictive value in evaluating therapeutic response to hormonal therapy.
Primary hormonal therapy (without surgical intervention) to preserve fertility in child-bearing
women with endometrial cancer has shown some degree of success, although the vast majority
of patients ended up receiving the definitive therapy (that is, total abdominal hysterectomy)
[86, 87]. As opposed to adjuvant radiotherapy, chemotherapy or combined radio-chemother‐
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apy, hormonal therapy is hardly ever considered as one of the “primary” adjuvant treatment
regimens in management of patients with endometrial cancer [86, 87]. Currently, hormonal
therapy is largely employed for management of patients with poor performance status or
recurrent/advanced/metastatic endometrial cancers, with the advantages of low morbidity,
few drug-related side effects and relatively suboptimal therapeutic response [86, 87].
The most frequently employed hormonal agents for management of endometrial cancer
include: progesterone/progestin, selective estrogen receptor modulators (SERMs), gonadotro‐
pin-releasing hormone (GnRH) agonists, and aromatase inhibitors [86-90].
5.1. Progesterone/progestin
Progesterone/progestin has been proven to be an effective inhibitor (suppressor) of endome‐
trial carcinogenesis mediated through estrogen exposure [91, 92].
Many retrospective studies and clinical trials have been conducted to evaluate the role of
multiple progestin-based hormonal therapy regimens in management of patients with
recurrent endometrial cancer. The most commonly used regimens are megestrol acetate (MA)
and medroxyprogesterone acetate (MPA).
In 1996, a meta-analysis of 6 randomized trials comprising a sum of 3339 patients with
endometrial cancer failed to produce any survival benefits when adjuvant progesterone/
progestin therapy was administered [93]. Moreover, a successively reported randomized
clinical trial recruiting more than 1000 patients with endometrial cancer also failed to produce
any survival benefits when adjuvant progesterone/progestin therapy was administered [94].
Furthermore, in 2011, a recently published Cochrane meta-analysis demonstrated no survival
benefits of adjuvant progesterone/progestin in 4556 patients with endometrial cancer [95]
5.2. Selective estrogen receptor modulators (SERMs)
The expression of ER in endometrial cancer justifies the use of selective estrogen receptor
modulators (SERMS), such as tamoxifen and raloxifene [96]. The tamoxifen-induced increased
risk of developing endometrial cancer is a well-known adverse effect and must always be
considered in mind [97], as opposed to raloxifene that is not associated with any endometrial
cancer risk.
Thigpen and partners [98] used adjuvant tamoxifen (2 doses of 20 mg/day) in management of
patients with recurrent and advanced endometrial cancer. The response rate was 10%. The
median progression-free survival and overall survival rates were roughly 2 and 9 months,
respectively. Raloxifene produced equally unsatisfactory results.
Arzoxifene is a modified drug of raloxifene. Two phase II clinical trials by McMeekin et al. [99]
and Burke et al. [100] explored the role of adjuvant arzoxifene (20 mg/day) for management
of patients with recurrent, metastatic and advanced endometrial cancer. The response rates
were 25% and 31%, respectively. The median response periods were approximately 19.3 and
12.9 months, respectively.
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Rendina and associates [101] compared the efficacy of adjuvant tamoxifen versus MPA in
patients with recurrent endometrial cancer, and response rates were roughly 53% and 56%,
respectively.
Pandya et al. [102] randomized 20 patients and 42 patients with endometrial cancer to receive
MA (standard progestin) and combination of MA plus tamoxifen, respectively. The response
rates were 20% (1 complete and 3 partial responses) and 19% (1 complete and 7 partial
responses), respectively. It was decided that the combination of MA plus tamoxifen did not
yield clinical benefits over MA alone in management of patients with advanced endometrial
cancer.
Whitney et al. [103] in a phase II trial of MPA (200 mg/week) plus tamoxifen (40 mg/day) in
patients with advanced and recurrent endometrial cancer demonstrated a 33% response rate
(13 partial and 6 complete responses among a total of 58 patients). The median progression-
free survival and overall survival were 3 month and 13 months, respectively. It was concluded
that daily tamoxifen (40 mg/day) and alternating weekly MPA (200 mg/week) constitutes an
effective therapeutic regimen in management of patients with recurrent and advanced
endometrial cancer.
5.3. Gonadotropin-releasing hormone (GnRH) agonists
Gonadotropin-releasing hormone (GnRH) agonists can effectively suppress estrogen produc‐
tion levels by ovarian cells ― a process mediated by down-regulation of GnRH receptors [87].
Multiple studies in the United Kingdom explored the usefulness of GnRH agonists in the
management of patients with recurrent endometrial cancer [104, 105]. In a phase II clinical trial,
6 out of 17 patients (35%) experienced a response rate at a median of 20 months without drug-
related toxicities [104]. A long-term follow-up study, five years afterwards, the same research
team documented that the response rate was 28% in 32 patients with recurrent endometrial
cancer [105]. The response rate was higher in the previously irradiated regions (35%) versus
non-irradiated regions (28%) of relapse. The study concluded that utilization of GnRH agonists
greatly exhibit beneficial anti-cancer outcomes in patients with recurrent and advanced
endometrial cancer, particularly in those patients who received previous radiation therapy.
Another GOG clinical trial explored the influence of Goserelin acetate (GnRH agonist) in 42
patients with advanced and recurrent endometrial cancer. A total of 5 patients (11%) experi‐
enced a response rate. The median progression-free survival and overall survival rates were
roughly 2 and 7.3 months, respectively [106].
5.4. Aromatase inhibitors (AIs)
Aromatase inhibitors (AIs), such as anastrozole and letrozole, directly block the aromatase
enzyme, and subsequently decrease the estrogen production and suppress its estrogen-driven
neoplastic endometrial proliferation [87].
A phase II clinical trial by Rose and colleagues [107] studied the efficacy of anastrozole (1 mg
a day for 28 days) in 23 patients with advanced or recurrent endometrial cancer. The response
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rate was 9% and progression-free interval ranged from 1 to 6 months. Despite the drug-related
adverse events were well-tolerated, it was concluded that anastrozole does not offer any
survival advantages.
Another multi-center phase II clinical trial by Ma and colleagues [108] studied the effect of
letrozole in 28 patients with metastatic or recurrent endometrial cancer who previously
received progestin-based and/or chemotherapy regimens. One patient (3.6%), two patients
(7.1%) and eleven patients (39%) experienced a complete response, a partial response and a
median 6.7-month stable disease, respectively. The median time to progression and overall
survival were approximately 4 and 9 months, respectively. The most frequently encountered
drug-related adverse events in a descending order were: hot flashes, grade I and II (28%),
followed by fatigue and anemia
In short, it can be concluded that AIs greatly failed to offer survival benefits in management
of patients with endometrial cancer
6. The role of molecular-target therapy in management of endometrial
As opposed to conventional cytotoxic drugs, molecular-targeted cytotoxic drugs are able to
differentiate between normal cells and cancerous cells, and therefore specifically damage only
the cancerous cells by inhibiting the cellular molecules/pathways associated with neoplastic
proliferation and metastasis [109].
6.1. Mammalian target of rapamycin (mTOR) inhibitors
PTEN genetic mutations are associated with reduced apoptosis and are implicated in more
than 80% of endometrioid cancer of the uterus [109].  The effects of PTEN genetic muta‐
tions can be decreased by utilizing mammalian target of rapamycin (mTOR) inhibitors (for
example, temsirolimus, ridaforolimus, everolimus, and AP2357) by interrupting phosphoi‐
nositide 3-kinase฀AKT฀mTOR pathway [109, 110]. In a phase II clinical trial of temsiroli‐
mus in previously chemotherapy-untreated patients with recurrent endometrial cancer, 26%
and 63% of patients experienced partial response and stable disease, respectively [111]. In
a phase II clinical trial of temsirolimus in previously chemotherapy-treated patients with
recurrent  endometrial  cancer,  7% and 44% of  patients  experienced partial  response  and
stable disease, respectively [112].
In a phase II clinical trial of ridaforolimus as a single agent in patients with advanced endo‐
metrial cancer, a total 29% of patients experienced clinical beneficial response in the form of
complete response, partial response or prolonged stable disease for more than 16 weeks [113].
In a phase II clinical trial of everolimus as a single agent in patients with recurrent endometrial
cancer, 21% of patients experienced confirmed clinical beneficial response in the form of
complete response, partial response or prolonged stable disease at 20 weeks after therapy [114].
There is an ongoing randomized controlled trial single-agent temsirolimus versus a combina‐
tion of temsirolimus and hormonal therapy [109]
Contemporary Gynecologic Practice168
6.2. Human Epidermal Growth Factor Receptor (EGFR) Inhibitors
Epidermal Growth Factor Receptor (EGFR) is frequently expressed in normal endometrial
tissues; however, its overexpression is correlated with advanced endometrial cancer and poor
prognosis [110]. Examples of EGFR inhibtors include erlotinib and gefitinib, both of which are
low-molecular weight tyrosine kinase inhibitors.
In a phase II clinical trial of erlotinib in 23 patients with recurrent endometrial cancer, only one
patient (4.3%) experienced partial response [115]. In a phase II clinical trial of gefitinib in 29
patients with recurrent endometrial cancer, only one patient (3.4%) experienced complete
response [116].
Cetuximab is a monoclonal antibody targeted against EGFR. A phase II clinical trial of
cetuximab in management of recurrent endometrial cancer is still ongoing [110].
Trastuzumab belongs to human EGFR type 2 (HER-2)-related inhibitors [110]. HER-2 overex‐
pression is implicated in the development of advanced endometrial cancer and poor prognosis
[117, 118], and specifically found in up to 20-30% of patients with serous endometrial cancer
[119]. A phase II clinical trial of trastuzumab in 33 patients with HER-2 amplified recurrent/
advanced endometrial cancer did not result in any clinical beneficial response [120]
Lapatinib is an inhibitor targeting EGFR and HER-2 receptors. A phase II clinical trial of
lapatinib in management of recurrent endometrial cancer is still ongoing [110].
6.3. Angiogenesis Inhibitors
Vascular  Endothelial  Growth  Factor  (VEGF)  plays  central  roles  in  angiogenesis  and
overexpression  is  a  feature  in  advanced  endometrial  cancer  and  correlated  with  poor
prognosis [110, 121].
In a phase II clinical trial of single agent bevacizumab (a recombinant humanized immuno‐
globulin monoclonal antibody targeted against VEGF) in 52 patients with recurrent endome‐
trial cancer, only 7 patients (around 14%) showed complete/partial response at 6 months
following treatment. The median progression-free survival and overall survival were roughly
4 and 11 months, respectively. The adverse side effects were tolerated [122]. Wright and
colleagues [123] studied the role of bevacizumab in 10 patients with recurrent endometrial
cancer. Only two (20%) and three (30%) patients responded to treatment and experienced
stable disease, respectively. A GOG 229-E phase II clinical trial of single-agent bevacizumab,
and GOG 229-G phase II clinical trial of a combination of bevacizumab and temsirolimus in
management of patients with metastatic endometrial cancer are still ongoing [109, 110].
Aflibercept is a fusion protein with high-affinity against VEGF receptors [110]. In a phase II
clinical trial of single agent Aflibercept in 44 patients with recurrent endometrial cancer, only
3 patients (around 8%) experienced partial response. Moreover, 18 patients (41%) experienced
progression-free survival of 6 months; however, of these, 8 patients had to withdraw afliber‐
cept secondary to drug-related adverse events. The median progression-free survival and
overall survival were roughly 3 and 15 months, respectively [124].
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Thalidomide possesses anti-angiogenetic action [110]. In a phase II clinical trial in 24 patients
with chemotherapy-unresponsive recurrent endometrial cancer, 3 patients (12.5%) experi‐
enced partial response and 2 patients (8.3%) had a progression-free survival of more than 6
months. The median progression-free survival and overall survival were roughly 1.7 and 6.3
months, respectively [125].
Sunitinib is a multi-kinase inhibitor with an anti-angiogenetic action. It is currently under
investigation in clinical trials to assess its effectiveness in management of patients with
recurrent endometrial cancer [109, 110].
The existing response rates to molecular-targeted regimen as single-agent treatment are largely
insignificant and additional randomized clinical trials are necessary, probably with a combi‐
nation of currently available treatments and an exploration for elements influencing molecular
targeted drug sensitivity.
7. Conclusion
• Management of endometrial cancer is challenging.
• Endometrial cancer is primarily treated with surgical staging.
• Comprehensive surgical staging for endometrial cancer is recommended (total hysterecto‐
my, bilateral salpingooophorectomy, peritoneal cytology, intraoperative bilateral pelvic
and para-aortic lymph node dissection). It allows accurate delineation of the extent of the
disease and subsequently allows identifying patients who may benefit from adjuvant
therapy.
• The extent of lymph node dissection (bilateral pelvic and/or para-aortic) in surgical staging
of patients with endometrial cancer, regardless of FIGO staging, remains controversial.
• As opposed to laparotomy, conventional laparoscopy ―whenever technically possible―
should be considered as the recommended (primary) approach for comprehensive surgical
staging in patients with endometrial cancer
• For patients with recurrent endometrial cancer, optimal cytoreduction (even if multiple) is
associated with increased disease-progression survival.
• For patients with recurrent endometrial cancer and peritoneal metastasis, the role of
hyperthemic intraperitoneal chemotherapy is still experimental. Despite initial promising
results, additional studies are needed.
• For high-risk patients with endometrial cancer, adjuvant treatment (radiation therapy,
chemotherapy, or both) is recommended, and appropriate selection of patients for adjuvant
therapy is critical.
• For high-risk patients with endometrial cancer, adjuvant pelvic external beam radiation
therapy is recommended over vaginal brachytherapy. Conversely, in low-risk patients with
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endometrial cancer, adjuvant vaginal brachytherapy, and not external beam radiation
therapy, should be primarily used (if deem necessary by treating physicans). Radiation
therapy can improve disease-free survival.
• For high-risk patients with endometrial cancer, carboplatin―placitaxel adjuvant chemo‐
therapeutic regimen is recommend over the standard doxorubicin―cisplatin (with or
without placitaxel) chemotherapeutic regimen, due to its well-tolerated drug-related
adverse effects and non-inferiority to the standard chemotherapeutic regimen. It is associ‐
ated with improved disease-free survival.
• For high-risk patients with endometrial cancer, a combination therapy of radiation therapy
and chemotherapy could probably decrease the disease progression and overall death.
• Hormonal therapy is not recommended, and its use should be restricted to clinical trials.
• Molecular-targeted therapy is not recommended, and its use should be restricted to clinical
trials.
• Long-term follow-up of patients is necessary.
• Further randomized controlled clinical trials are needed.
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